Bicycle Therapeutics has been granted a patent for polypeptides covalently bound to molecular scaffolds, creating high-affinity binders of TSLP. The invention includes pharmaceutical compositions and the use of these peptide ligands in treating TSLP-mediated diseases. GlobalData’s report on Bicycle Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Bicycle Therapeutics Plc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Bicycle Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Bicycle Therapeutics's grant share as of January 2024 was 16%. Grant share is based on the ratio of number of grants to total number of patents.

High affinity peptide binders for thymic stromal lymphopoietin (tslp)

Source: United States Patent and Trademark Office (USPTO). Credit: Bicycle Therapeutics Plc

A recently granted patent (Publication Number: US11866518B2) discloses a peptide ligand specific for thymic stromal lymphopoietin (TSLP) that comprises a polypeptide with at least three cysteine residues separated by loop sequences. The peptide ligand forms covalent bonds with a molecular scaffold, resulting in the formation of at least two polypeptide loops. The patent lists various amino acid sequences for the peptide ligand, including examples like Ac-(SEQ ID NO: 1), tertBuCO-(SEQ ID NO: 3), and A-(SEQ ID NO: 38)-ADGDML, among others. These peptide ligands can be used for specific binding to TSLP.

Moreover, the patent also covers a multimeric binding complex composed of at least two peptide ligands, where each ligand follows the specific structure outlined in the claims. The multimeric binding complex can be a dimeric or trimeric moiety, providing versatility in the design and application of the ligands. Additionally, the patent specifies the use of a molecular scaffold known as 1,1',1?-(1,3,5-triazinane-1,3,5-triyl)triprop-2-en-1-one (TATA) in the construction of the peptide ligands. Furthermore, the patent includes details on the pharmaceutical composition comprising the peptide ligand and pharmaceutically acceptable salts, along with the use of specific linker moieties and excipients in the formulation.

To know more about GlobalData’s detailed insights on Bicycle Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies